Sarepta to Present Late-Breaking ELEVIDYS Data at WMS Congress; Event Could Shed Light on Ambulatory Use

What happened

Sarepta Therapeutics announced it will present new data from its Duchenne muscular dystrophy portfolio at the World Muscle Society Congress from Sept 29 to Oct 3, including a late-breaking poster on ELEVIDYS efficacy and safety in older ambulatory patients. This announcement comes after a turbulent period for Sarepta, marked by an FDA-imposed boxed warning and ambulatory-only restriction on ELEVIDYS, a temporary shipment suspension, and disappointing Q4'25 sales that missed consensus. The company is attempting to rebuild scientific and commercial credibility by presenting data that could address lingering questions about the therapy's benefit-risk profile in a broader ambulatory population beyond the original trial age range. However, the press release provides no data details, so investors must await the actual presentation to determine whether the findings alleviate concerns about liver safety and durability or reinforce the existing regulatory overhang. Given that the master report rates SRPT a WAIT with key milestones tied to Q1'26 infusion recovery and FDA actions, this conference represents a potential catalyst but not a near-term thesis changer until the data are evaluated.

Implication

Longer-term, the data could either strengthen the case for ELEVIDYS expansion into older ambulatory patients and improve sentiment, or if safety concerns persist, further constrain the franchise and validate the bear scenario of a $10 implied value.

Thesis delta

The WAIT thesis remains intact. This announcement introduces a potential positive catalyst in the form of new ELEVIDYS data, but without seeing the data, it does not change the balance of risks. We will update our view if the WMS presentation reveals compelling safety/efficacy results that could shift FDA posture or commercial trajectory.